RxDoctor Payments Data

McKenzie Janak, APRN

Family · Bay City, TXNPI 1942958756

Payments from drug & device makers

$2,147in general payments, 2019–2025

Across 62 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$923
  • Paratek Pharmaceuticals, Inc.$236
  • Novo Nordisk$224
  • AbbVie$137
  • Gilead$136
  • Inspire Medical Systems, Inc.$92
  • plus $399 from 11 others

What the payments were for

  • Food & beverage$2,147100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,147 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$42,620
Medicare patients
118
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,250
MyrbetriqMirabegron14$3,662
Albuterol Sulfate HfaAlbuterol Sulfate33$1,263
Bumetanide11$760
Gabapentin52$708
Tramadol Hcl48$600
Testosterone Cypionate11$589
Acetaminophen-CodeineAcetaminophen With Codeine26$568
Tizanidine Hcl20$462
Pregabalin24$406
Pantoprazole Sodium28$406
Atorvastatin Calcium58$384
Fluoxetine Hcl15$360
Methylprednisolone39$332
Levothyroxine Sodium23$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$923$8,25013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Bay City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →